Illinois ADVANCE Newsletter

Summer 2026



FDA UPDATE

New Sunscreen Ingredient Expands UV Protection

The FDA has approved bemotrizinol - the first new sunscreen ingredient in more than 25 years!

STAYING CONNECTED
Successful Outreach

PAGE 2
PAGE 3

CLINICAL UPDATE
Ozempic Pill

NEW SUNSCREEN
Bemotrizinol

PAGE 4

IL ADVANCE PUBLISHED
Impact of Academic Detailing

IDPH SURVEY
Men's Health

PAGE 5

TIPS
Managing Stress

STAYING CONNECTED, ADVANCING TOGETHER





At IL ADVANCE, we are committed to staying at the forefront of healthcare by actively engaging with professional organizations and conferences throughout the year.

In 2026, we've participated in key meetings such as the AMCP Annual Meeting and the ISMS Annual Meeting, with continued involvement across Illinois this fall through presentations, booths, and collaborative sessions.

Our presence at conferences including ACCP, IPHA, IPHCA, Women in Medicine, IAPA, Power of Nursing Leadership, IL Lyme Association/IDPH and NaRCAD reflects our dedication to staying current, sharing expertise, and learning alongside fellow healthcare professionals.

We invite you to stay connected with IL ADVANCE—join us at upcoming events, engage in our educational offerings, and collaborate with us as we continue moving forward together in advancing patient care.

UPCOMING PRESENTATIONS

Evidence-based sessions on timely clinical topics across Illinois

UPCOMING BOOTHS

Visit us at conferences to connect and access free resources

EDUCATIONAL OUTREACH

Continuing to provide high-quality education for prescribers and pharmacists

ACADEMIC DETAILING

One-on-one, practice-based support to implement guideline-concordant care

CLINICAL UDPATE: TRANSITIONING PATIENTS FROM RYBELSUS® TO OZEMPIC® PILL

With the introduction of the new oral semaglutide formulation (OZEMPIC®), transitioning patients from RYBELSUS® requires several key clinical and operational considerations.

Key Points for Conversion

- New prescription required: Patients cannot be automatically switched; a new prescription with updated dose strengths and NDC is necessary.
- No direct dose conversion: Despite similar efficacy, the updated tablets have different strengths and improved bioavailability, requiring retitration.

Recommended Titration

Day(s) 1-30	1.5 mg once daily (initial dose)
Days 31-60	4 mg once daily
Days 61+	9 mg once daily if additional glycemic control is needed

Avoid switching between formulations during the initiation phase.

Clinical Considerations

- Same molecule, similar efficacy and safety as prior oral semaglutide
- Expect potential temporary changes in glycemic control during retitration
- Reinforce administration instructions and adherence
- Monitor for gastrointestinal tolerability and hypoglycemia risk (if on insulin/ sulfonylureas)

Bottom Line

Transitioning is a formulation change, not a therapeutic switch, but requires:

- New prescribing workflows
- Structured dose escalation
- Clear patient counseling to maintain continuity of care



New FDA-Approved Sunscreen Ingredient Expands UV Protection Options

For the first time in more than 25 years, the FDA has approved a new sunscreen active ingredient. **Bemotrizinol**, a broad-spectrum UV filter used in Europe since 1999, is now approved for over-the-counter sunscreens for adults and children 6 months and older.

Bemotrizinol provides protection against both **UVA** and **UVB** rays in a single ingredient, offering comprehensive sun protection with minimal skin irritation and low systemic absorption. Unlike many mineral sunscreens, it does not leave a visible white cast, which may improve user acceptance and adherence.

The approval is significant because bemotrizinol is the first new sunscreen filter approved by the FDA since 1999 and the first organic UV filter to receive a **Generally Recognized as Safe and Effective (GRASE)** designation in more than two decades.

Why it matters: UVA rays contribute to skin aging and long-term skin damage, while UVB rays cause sunburn and increase skin cancer risk. Broad-spectrum protection against both is essential for effective sun safety. Bemotrizinol provides healthcare professionals and consumers with a new option for effective, cosmetically appealing sun protection.

Illinois ADVANCE

IL ADVANCE Team Publishes Academic Detailing Review

We are proud to share that members of the IL ADVANCE team recently published an article in the *Journal of Pharmacy Practice* titled, "**The Impact of Academic Detailing on Clinician and Patient Outcomes: A Narrative Review**."

This publication examines the growing body of evidence surrounding academic detailing and its influence on clinician behavior, prescribing practices, and patient outcomes. The review highlights how personalized, evidence-based educational outreach can support quality improvement efforts and enhance patient care across healthcare settings.

This achievement reflects IL ADVANCE's ongoing commitment to advancing evidence-based practice, promoting clinician education, and improving health outcomes throughout Illinois and beyond.

Congratulations to our authors and collaborators on this important contribution to literature!

Kudos to our authors:

Sajitha Purathur, PharmD
Dima Cheetany, PharmD
Tina Griffin, MLIS
Sonia Shah Dave, PharmD
Amy Madhiwala, PharmD
Brianna McQuade Hudak, PharmD, BCACP, MHPE
Liana Osis, PharmD
Chintan Patel, PharmD, MPH, BCPS

Men's Health Community Initiative

The **Illinois Department of Public Health** and the **University of Illinois System** are launching a statewide initiative to better understand and support men's health needs across our communities. This QR code invites residents and stakeholders to share their experiences through a brief survey or engagement session to help shape future programs and resources.

IDPH

Wellness Corner for Busy Physicians

Strategy #1: Identify & Manage Your Stress Triggers

Not all stress comes from the same place. Some days it's workload. Other days it's a difficult interaction, time pressure, or feeling like you can't catch up.

Start by noticing patterns:

- When do you feel most overwhelmed?
- What situations leave you drained versus energized?
- Are there specific times of day or tasks that spike your stress?

Once you identify your common triggers, you can plan ahead. That might mean building in a short reset break after a high-stress task, preparing talking points for challenging conversations, or adjusting your workflow when possible. You may not be able to eliminate stressors — but you can reduce their impact.

IllinoisADVANCE.uic.edu
IllinoisADVANCE@uic.edu